Creating paradigm shift in oligonucleotide synthesis and accelerate the innovation of its therapeutics.

With our unique Blockmer-based oligonucleotide synthesis technology, we offer extremely high purity oligonucleotides in mg to ton scale at reasonable prices. ・Oligonucleotide Synthesis Service ・Blockmer™ intermediates Sales ・Nucleotide analog synthesis Service ・mRNA production solution Service

OUR PRODUCT
https://www.natias.co.jp/index.php/en/product-2/

Oligonucleotides Synthesis Service With our propriety Blockmer™ ntermediates (available for purchase), we develop and manufacture oligonucleotide CpG adjuvants, primers, and probes for PCR genetic testing, as well as for pharmaceutical applications.

Contact
https://www.linkedin.com/company/natias/
CEO
Masanori Kataoka
CEO
https://www.linkedin.com/in/%E6%AD%A3%E5%85%B8-%E7%89%87%E5%B2%A1-3414b2195/
FOUNDER
Masanori Kataoka
CEO
https://www.linkedin.com/in/%E6%AD%A3%E5%85%B8-%E7%89%87%E5%B2%A1-3414b2195/
Techno Network Shikoku Co., Ltd.
Voice from Acceralator
CIC

Oligonucleotide API, 2015 NATiAS produces oligonucleotides (a new drug modality) at large volumes, low cost, and high purity. Their unique Blockmer oligonucleotide synthesis technology can achieve large scale production of oligonucleotides without many impurities generated with current methods using monomers. Oligonucleotide therapeutics are being applied more broadly in areas like metabolic, infectious, Alzheimer’s, and Huntington’s disease and in diagnosis and mRNA vaccines. The high purity and cost-effective oligonucleotides production at scale offered by NATiAS has the potential to meet the rapidly growing demands from many pharmaceutical companies.